Abstract
The knowledge about the pathogenesis and the development of the neurodegeneration associated with
Keywords: neurodegeneration, amyloid, cholinesterase inhibitors, drug design, molecular modelling
Current Pharmaceutical Design
Title: Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics
Volume: 10 Issue: 25
Author(s): Maurizio Recanatini and Piero Valenti
Affiliation:
Keywords: neurodegeneration, amyloid, cholinesterase inhibitors, drug design, molecular modelling
Abstract: The knowledge about the pathogenesis and the development of the neurodegeneration associated with
Export Options
About this article
Cite this article as:
Recanatini Maurizio and Valenti Piero, Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics, Current Pharmaceutical Design 2004; 10 (25) . https://dx.doi.org/10.2174/1381612043383313
DOI https://dx.doi.org/10.2174/1381612043383313 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Observation of Pain in Dementia
Current Alzheimer Research Evolution of Global and Local Grey Matter Atrophy on Serial MRI Scans During the Progression from MCI to AD
Current Alzheimer Research Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Voxel-Based Morphometry of the Human Brain: Methods and Applications
Current Medical Imaging Neurovascular Changes in Acute, sub-Acute and Chronic Mouse Models of Parkinson’s Disease
Current Neurovascular Research Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics Structure-Function Relationship of Vpr: Biological Implications
Current HIV Research C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Molecular Imaging in the Default Mode Network
Current Molecular Imaging (Discontinued) Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design Association of Cerebrospinal Fluid Adiponectin Levels With Cerebral Glucose Metabolism In Mild Cognitive Impairment: A Pilot Study
Current Alzheimer Research Pharmacological Treatment of Cognitive Symptoms in Alzheimer's Disease
Current Psychopharmacology Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Inhibition of β-Amyloid Aggregation by Albiflorin, Aloeemodin and Neohesperidin and their Neuroprotective Effect on Primary Hippocampal Cells Against β-Amyloid Induced Toxicity
Current Alzheimer Research Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research Cognitive Dysfunction in Depression: Lessons Learned from Animal Models
CNS & Neurological Disorders - Drug Targets Mediterranean Diet and Risk of Dementia
Current Alzheimer Research